Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRPA1 | O75762 | 1/20 | 0.39 |
| ▸ | CA2 | P00918 | 1/20 | 0.39 |
| ▸ | POLB | P06746 | 1/20 | 0.38 |
| ▸ | NPC1 | O15118 | 3/20 | 0.37 |
| ▸ | RAB9A | P51151 | 3/20 | 0.37 |
| ▸ | MAPT | P10636 | 1/20 | 0.37 |
| ▸ | ELANE | P08246 | 2/20 | 0.34 |
| ▸ | MMP2 | P08253 | 4/20 | 0.33 |
| ▸ | MMP3 | P08254 | 2/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.32 |
| ▸ | PYGL | P06737 | 1/20 | 0.32 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.32 |
| ▸ | Q9HBH1 | 1/20 | 0.31 | |
| ▸ | HDAC4 | P56524 | 1/20 | 0.31 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.31 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL635858 | 1.00 | TRPA1 (0.39) | TRPA1CA2POLBNPC1RAB9A | |
| SCHEMBL4372546 | 1.00 | TRPA1 (0.39) | TRPA1CA2POLBNPC1RAB9A | |
| SCHEMBL14943545 | 0.83 | TRPA1 (0.39) | TRPA1POLBNPC1RAB9AMAPT | |
| SCHEMBL12401122 | 0.81 | TRPA1 (0.38) | TRPA1POLBNPC1RAB9AMAPT | |
| SCHEMBL636880 | 0.79 | TRPA1 (0.37) | TRPA1POLBNPC1RAB9AMAPT | |
| SCHEMBL636879 | 0.79 | TRPA1 (0.37) | TRPA1POLBNPC1RAB9AMAPT | |
| SCHEMBL12571864 | 0.78 | TRPA1 (0.36) | TRPA1POLBNPC1RAB9AMAPT | |
| SCHEMBL12482473 | 0.78 | TRPA1 (0.36) | TRPA1POLBNPC1RAB9AMAPT | |
| SCHEMBL10107206 | 0.78 | CTSK (0.37) | TRPA1CA2POLBNPC1RAB9A | |
| SCHEMBL13135688 | 0.77 | TRPA1 (0.53) | TRPA1POLBMAPTSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 48 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2014061034-A1 | PROCESS FOR PREPARATION OF BOCEPREVIR AND INTERMEDIATES THEREOF | MSN LABORATORIES LIMITED (IN) | 2014-04-24 | — | — | WO | claimed |
| WO-2009114633-A1 | PROCESS FOR THE PREPARATION OF (3S)-3-AMINO-N-CYCLOPROPYL-2-HYDROXYALKANAMIDE DERIVATIVES | VIROBAY, INC. (US) | 2009-09-17 | — | — | WO | claimed |
| US-20090234127-A1 | PROCESS FOR THE PREPARATION OF (3S)-3-AMINO-N-CYCLOPROPYL-2-HYDROXYALKANAMIDE DERIVATIVES | VIROBAY, INC. (US) | 2009-09-17 | — | — | US | claimed |
| WO-2014061034-A1 | PROCESS FOR PREPARATION OF BOCEPREVIR AND INTERMEDIATES THEREOF | MSN LABORATORIES LIMITED (IN) | 2014-04-24 | — | — | WO | disclosed |
| US-8518874-B2 | HCV inhibitors | VIROBAY, INC. (US) | 2013-08-27 | — | — | US | disclosed |
| US-8431733-B2 | Process for the preparation of (3S)-3-amino-N-cyclopropyl-2-hydroxyalkanamide derivatives | VIROBAY, INC. (US) | 2013-04-30 | — | — | US | disclosed |
| US-8211897-B2 | Inhibitors of cathepsin B | VIROBAY, INC. (US) | 2012-07-03 | — | — | US | disclosed |
| US-8211897-B2 | Inhibitors of cathepsin B | VIROBAY, INC. (US) | 2012-07-03 | — | — | US | disclosed |
| US-8163937-B2 | Process for preparing (1R,2S,5S)-N-[(1S)-3-amino-1-(cyclobutylmethyl)-2,3-dioxopropyl]-3-[(2S)-2-[[[(1,1-dimethylethyl)amino]-carbonyl]amino]-3,3-dimethyl-1-oxobutyl]-6,6-dimethyl-3-azabicyclo[3.1.0]hexane-2-carboxamide | SCHERING CORPORATION (US) | 2012-04-24 | — | — | US | disclosed |
| US-8163937-B2 | Process for preparing (1R,2S,5S)-N-[(1S)-3-amino-1-(cyclobutylmethyl)-2,3-dioxopropyl]-3-[(2S)-2-[[[(1,1-dimethylethyl)amino]-carbonyl]amino]-3,3-dimethyl-1-oxobutyl]-6,6-dimethyl-3-azabicyclo[3.1.0]hexane-2-carboxamide | SCHERING CORPORATION (US) | 2012-04-24 | — | — | US | disclosed |
| EP-2431379-A2 | HCV inhibitors | Virobay, Inc. (US) | 2012-03-21 | — | — | EP | disclosed |
| EP-1641754-B1 | PROCESS AND INTERMEDIATES FOR THE PREPARATION OF (1R, 2S, 5S)-3- AZABICYCLO[ 3, 1, 0]HEXANE-2-CARBOXAMIDE, N- [3-AMINO -1-(CYCLOBUTYLMETHYL)-2, 3-DIOXOPROPYL] ]-3- [ (2S)- 2-[[[1, 1-DIMETHYLETHYL ]AMINO]CARBONYLA MINO ]-3, 3-DIMETHYL-1-OXOBUTYL] -6, 6-DIMETHYL | SCHERING CORP (US) | 2008-03-26 | — | — | EP | disclosed |
| US-7326795-B2 | Process and intermediates for the preparation of (1R,2S,5S)-3-azabicyclo[3,1,0]hexane-2-carboxamide, N-[3-amino-1-(cyclobutylmethyl)-2,3-dioxopropyl]-3-[(2S)-2-[[[1,1-dimethylethyl]amino]carbonylamino]-3,3-dimethyl-1-oxobutyl]-6,6-dimethyl | SCHERING CORPORATION (US) | 2008-02-05 | — | — | US | disclosed |
| US-7326795-B2 | Process and intermediates for the preparation of (1R,2S,5S)-3-azabicyclo[3,1,0]hexane-2-carboxamide, N-[3-amino-1-(cyclobutylmethyl)-2,3-dioxopropyl]-3-[(2S)-2-[[[1,1-dimethylethyl]amino]carbonylamino]-3,3-dimethyl-1-oxobutyl]-6,6-dimethyl | SCHERING CORPORATION (US) | 2008-02-05 | — | — | US | disclosed |
| US-20070054864-A1 | 1-[2S-(3-Tert-butylureido)-3,3-dimethylbutyryl]-4R-(7-methoxy-2-pyrazol-1-yl-quinolin-4-yloxy)-pyrrolidine-2S-carboxylic acid (1S-cyclopropylaminooxalylbutyl)amide, for example; useful in treating hepatitis C infections | QUEST DIAGNOSTICS INVESTMENTS LLC | 2007-03-08 | — | — | US | disclosed |
| US-20070054864-A1 | 1-[2S-(3-Tert-butylureido)-3,3-dimethylbutyryl]-4R-(7-methoxy-2-pyrazol-1-yl-quinolin-4-yloxy)-pyrrolidine-2S-carboxylic acid (1S-cyclopropylaminooxalylbutyl)amide, for example; useful in treating hepatitis C infections | QUEST DIAGNOSTICS INVESTMENTS LLC | 2007-03-08 | — | — | US | disclosed |
| WO-2007005838-A2 | HCV INHIBITORS | VIROBAY, INC. (US) | 2007-01-11 | — | — | WO | disclosed |
| WO-2007005838-A2 | HCV INHIBITORS | VIROBAY, INC. (US) | 2007-01-11 | — | — | WO | disclosed |
| WO-2004113294-A1 | PROCESS AND INTERMEDIATES FOR THE PREPARATION OF (1R, 2S, 5S)-3-AZABICYCLO[3, 1, 0]HEXANE-2-CARBOXAMIDE, N-[3-AMINO-1-(CYCLOBUTYLMETHYL)-2, 3-DIOXOPROPYL] ]-3-[(2S)-2-[[[1, 1-DIMETHYLETHYL]AMINO]CARBONYLAMINO]-3, 3-DIMETHYL-1-OXOBUTYL]-6, 6-DIMETHYL | SCHERING CORPORATION (US) | 2004-12-29 | — | — | WO | disclosed |
| WO-2004103996-A1 | HEPATITIS C INHIBITOR COMPOUNDS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2004-12-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090234127-A1 | PROCESS FOR THE PREPARATION OF (3S)-3-AMINO-N-CYCLOPROPYL-2-HYDROXYALKANAMIDE DERIVATIVES | CTSS, CTSV, CTSE | TRPA1 3131/4885CA2 2125/4885POLB 1664/4885 |
| US-20070054864-A1 | 1-[2S-(3-Tert-butylureido)-3,3-dimethylbutyryl]-4R-(7-methoxy-2-pyrazol-1-yl-quinolin-4-yloxy)-pyrrolidine-2S-carboxylic acid (1S-cyclopropylaminooxalylbutyl)amide, for example; useful in treating hepatitis C infections | HAVCR2, EIF2AK2, GTF3C1 | TRPA1 4504/4885CA2 4790/4885POLB 263/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.